Imo Ebong is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4860 Y St Ste 2860
Sacramento, CA 958172307
Telephone
916-734-8426Provider last certified this registry record 21 Feb 2024.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20255 payments$47,000openpaymentsdata.cms.gov ↗
- Alnylam Pharmaceuticals Inc.Program year20257 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
63.1%Beta blocker11.9%Metoprolol Succinate61%Carvedilol27%Bisoprolol Fumarate7%Metoprolol Tartrate5%Part D<11 patientsLoop diuretic9.5%Furosemide54%Bumetanide35%Torsemide11%Part D<11 patients+ 16 more classes in this area
Metabolism & gastrointestinal
21%SGLT2 inhibitor13.2%Jardiance67%Farxiga33%Part D≥55 patientsPotassium supplement2.6%Potassium Chloride100%Part D≥27 patients+ 4 more classes in this area
Nervous system
8.7%Other nervous system drugs8.7%Vyndamax100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2023 per NIH RePORTER. The latest:
- Adipokines, Sex Hormones and Cardiac Dysfunction in Postmenopausal Women of the MESA Study – An analysis of Secondary Data
University of California at Davis
FY2023$127,519R21HL165018 - Adipokines, Sex Hormones and Cardiac Dysfunction in Postmenopausal Women of the MESA Study – An analysis of Secondary Data
University of California at Davis
FY2022$142,955R21HL165018
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”